- Home
- BTMD vs ALXO Comparison
BTMD vs ALXO Comparison
Compare BTMD & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- ALXO
- Stock Information
- Founded
- BTMD 2012
- ALXO 2015
- Country
- BTMD United States
- ALXO United States
- Employees
- BTMD N/A
- ALXO N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- BTMD Health Care
- ALXO Health Care
- Exchange
- BTMD Nasdaq
- ALXO Nasdaq
- Market Cap
- BTMD 127.8M
- ALXO 102.3M
- IPO Year
- BTMD N/A
- ALXO 2020
- Fundamental
- Price
- BTMD $2.85
- ALXO $1.90
- Analyst Decision
- BTMD Buy
- ALXO Strong Buy
- Analyst Count
- BTMD 2
- ALXO 6
- Target Price
- BTMD $6.00
- ALXO $3.30
- AVG Volume (30 Days)
- BTMD 114.6K
- ALXO 752.9K
- Earning Date
- BTMD 11-11-2025
- ALXO 11-06-2025
- Dividend Yield
- BTMD N/A
- ALXO N/A
- EPS Growth
- BTMD 642.53
- ALXO N/A
- EPS
- BTMD 0.88
- ALXO N/A
- Revenue
- BTMD $199,073,000.00
- ALXO N/A
- Revenue This Year
- BTMD N/A
- ALXO N/A
- Revenue Next Year
- BTMD $4.85
- ALXO N/A
- P/E Ratio
- BTMD $3.26
- ALXO N/A
- Revenue Growth
- BTMD 6.32
- ALXO N/A
- 52 Week Low
- BTMD $2.76
- ALXO $0.40
- 52 Week High
- BTMD $6.98
- ALXO $2.27
- Technical
- Relative Strength Index (RSI)
- BTMD 31.72
- ALXO 63.51
- Support Level
- BTMD $2.82
- ALXO $1.83
- Resistance Level
- BTMD $3.07
- ALXO $2.27
- Average True Range (ATR)
- BTMD 0.12
- ALXO 0.20
- MACD
- BTMD -0.01
- ALXO 0.01
- Stochastic Oscillator
- BTMD 9.26
- ALXO 67.54
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.